Stage IV Lung Cancer AJCC v8 — Expanded Access Programs
Overview
Right2Hope maintains a directory of 54 expanded access programs, clinical trials, and compassionate use pathways listed for Stage IV Lung Cancer AJCC v8. Each entry below was sourced from sponsor disclosures and public clinical-trial registries. Use this hub to understand the breadth of ongoing research, identify sponsors with stage iv lung cancer ajcc v8 programs, and link out to specific protocols for eligibility, contact, and request details. Of these, 27 programs are currently active or recruiting, with the remaining 27 in other lifecycle stages. Sponsors actively running programs in this area include National Cancer Institute (NCI), M.D. Anderson Cancer Center, SWOG Cancer Research Network, City of Hope Medical Center, NRG Oncology, and others.
By recruiting status
Snapshot of where every Stage IV Lung Cancer AJCC v8 program currently sits in its lifecycle.
- Active / Recruiting27
- Inactive27
Top sponsors
Organisations running the most Stage IV Lung Cancer AJCC v8 programs in the directory.
- National Cancer Institute (NCI)11 programs
- M.D. Anderson Cancer Center8 programs
- SWOG Cancer Research Network7 programs
- City of Hope Medical Center4 programs
- NRG Oncology4 programs
- Emory University3 programs
- Roswell Park Cancer Institute3 programs
- University of Washington3 programs
- Mayo Clinic2 programs
- Alliance for Clinical Trials in Oncology1 program
Stage IV Lung Cancer AJCC v8 programs (54)
Sorted by recruiting status, then alphabetically by program name. Click any program to view eligibility, locations, and sponsor contact details.
- A Vaccine Study for Treating Stage IV Non-Small Cell Lung Cancer — University of Washington
- Study on Adding Cemiplimab to Usual Treatment for Advanced Non-Small Cell Lung Cancer After Previous Chemotherapy and Immunotherapy — SWOG Cancer Research Network
- Study on Danvatirsen and Durvalumab for Treating Advanced Pancreatic, Lung, and Colorectal Cancers — M.D. Anderson Cancer Center
- Study on Diclofenac for Treating Metastatic Non-Small Cell Lung Cancer with Immunotherapy — Emory University
- Study on Grid Radiation Therapy and Immunotherapy for Stage IV Non-Small Cell Lung Cancer — Mayo Clinic
- Study on GT103 and Pembrolizumab for Treating Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Cancer — Roswell Park Cancer Institute
- Study on Avoiding the Hippocampus During Radiation for Treating Cancer Spread to the Brain and Spinal Fluid — University of Washington
- Study on Biomarkers to Predict Immunotherapy Response and Second-line Treatment in Advanced Non-small Cell Lung Cancer — City of Hope Medical Center
- Study on Morning Versus Afternoon Immunotherapy for Treating Advanced or Metastatic Solid Tumors — OHSU Knight Cancer Institute
- Study on Osimertinib With or Without Bevacizumab for Treating EGFR Positive Non-small Cell Lung Cancer with Brain Metastases — National Cancer Institute (NCI)
- Phase 2 Study of DoceRamPem for Patients with Advanced or Returning Non-Small Cell Lung Cancer After Standard Treatments — Emory University
- Study on Photon Craniospinal Irradiation for Treating Cancer Spread to Brain and Spinal Fluid from Breast or Lung Cancer — City of Hope Medical Center
- Study on Sotorasib and Trastuzumab Deruxtecan for Treating Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation — National Cancer Institute (NCI)
- Study on Split-Course Radiation Therapy with Pembrolizumab and Optional Chemotherapy for Stage IV Lung Cancer — Vanderbilt-Ingram Cancer Center
- Study on Stereotactic Radiosurgery for Treating Brain Metastasis in Small Cell Lung Cancer Patients — M.D. Anderson Cancer Center
- Targeted Treatment for Advanced Non-Small Cell Lung Cancer with a MET Gene Change — SWOG Cancer Research Network
- Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer — SWOG Cancer Research Network
- Study on Telaglenastat Hydrochloride and Osimertinib for Treating Stage IV Non-small Cell Lung Cancer with EGFR Mutation — National Cancer Institute (NCI)
- Study Comparing Longer Radiation Therapy to Usual Radiation Therapy for Cancer Spread to the Brain — NRG Oncology
- Study Comparing Proton Radiation Therapy to Standard Radiation for Cancer Spread to Brain and Spinal Fluid — NRG Oncology
- Study on Adding Cabozantinib to Standard Immune Therapy for Non-Small Cell Lung Cancer — National Cancer Institute (NCI)
- Study on Combining Iadademstat with Atezolizumab or Durvalumab to Improve Outcomes for Small Cell Lung Cancer — National Cancer Institute (NCI)
- Study on Combining MLN4924, Carboplatin, and Paclitaxel for Advanced Non-Small Cell Lung Cancer After Immunotherapy — National Cancer Institute (NCI)
- Study on Pembrolizumab With or Without Chemotherapy for Patients Aged 70 and Older With Advanced Non-Small Cell Lung Cancer — Alliance for Clinical Trials in Oncology
- Study on Timing of Pembrolizumab Alone or With Chemotherapy for First-Line Treatment in Advanced Non-Small Cell Lung Cancer — National Cancer Institute (NCI)
- Study on Combination Immunotherapy Treatment (N-803 and Pembrolizumab) Versus Usual Treatment for Advanced Non-small Cell Lung Cancer — SWOG Cancer Research Network
- Study on Trametinib and Pembrolizumab for Treating Recurrent Non-small Cell Lung Cancer — M.D. Anderson Cancer Center
- Study on Anti-CTLA4-NF mAb, Nivolumab, and Targeted Radiation Therapy for Treating Metastatic Solid Tumors — M.D. Anderson Cancer Center
- Study on Avapritinib for Treating CKIT or PDGFRA Mutation-Positive Advanced or Metastatic Solid Tumors — M.D. Anderson Cancer Center
- Study on Biologically Guided Radiation Therapy and Stereotactic Body Radiation Therapy with Osimertinib for Treating EGFR Positive Non-Small Cell Lung Cancer — City of Hope Medical Center
- Cemiplimab for Treating Untreated Brain Metastases in Patients with PD-L1 ≥ 50% Non-Small Cell Lung Cancer — City of Hope Medical Center
- Study Comparing Chemotherapy Plus Immunotherapy vs. Immunotherapy Alone for Older Adults with Advanced Lung Cancer (ACHIEVE Trial) — National Cancer Institute (NCI)
- Study on CIMAvax Vaccine, Nivolumab, and Pembrolizumab for Treating Advanced Lung and Head and Neck Cancers — Roswell Park Cancer Institute
- Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer with EGFR and MET Gene Changes — SWOG Cancer Research Network
- Study on CPI-613 (Devimistat) with Hydroxychloroquine and 5-Fluorouracil or Gemcitabine for Treating Advanced Solid Tumors — Northwestern University
- Study on Defactinib, Avutometinib, and Nivolumab for Treating Advanced Non-Small Cell Lung Cancer with LKB1 Mutation — Emory University
- Study on EMB-01 and Osimertinib for Patients with EGFR Mutant Lung Cancer — Shanghai EpimAb Biotherapeutics Co., Ltd.
- Study on Niraparib, Temozolomide, and Atezolizumab for Treating Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer — Jonsson Comprehensive Cancer Center
- Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer — M.D. Anderson Cancer Center
- Study on Olaparib and Durvalumab with Chemotherapy and Radiation for Treating Extensive-Stage Small Cell Lung Cancer (PRIO Trial) — M.D. Anderson Cancer Center
- Study on Osimertinib With or Without Bevacizumab for Initial Treatment of EGFR-Mutant Lung Cancer — National Cancer Institute (NCI)
- Study on Using Panitumumab-IRDye800 to Detect Lung Cancer During Surgery — Eben Rosenthal
- Personalized Vaccine with Pembrolizumab for Treating Advanced Solid Tumors — Mayo Clinic
- Study on Photoimmunotherapy with ASP-1929 and Cemiplimab for Treating Advanced Non-Small Cell Lung Cancer — Roswell Park Cancer Institute
- Study on Plinabulin with Radiation and Immunotherapy for Advanced Cancers After PD-1 or PD-L1 Treatment — M.D. Anderson Cancer Center
- Study on Ramucirumab and Pembrolizumab vs Usual Care for Advanced or Returning Non-Small Cell Lung Cancer — SWOG Cancer Research Network
- Subcutaneous Atezolizumab for Treating Non-small Cell Lung Cancer — University of Southern California
- Study on SX-682 and Pembrolizumab for Treating Advanced or Returning Non-Small Cell Lung Cancer — University of Washington
- Targeted Treatment for ALK Positive Patients Previously Treated for Non-squamous Non-small Cell Lung Cancer — National Cancer Institute (NCI)
- Temozolomide and Atezolizumab as Second or Third Line Treatment for Metastatic or Recurrent Small Cell Lung Cancer — Dwight Owen
- Study Comparing High-Dose Radiation to Specific Brain Cancer Sites Versus Whole Brain Radiation Avoiding Memory Areas to Prevent Memory and Thinking Loss — NRG Oncology
- Study on Adding Radiation Therapy to Immunotherapy for Stage IV Non-Small Cell Lung Cancer Patients Without PD-L1 Marker — National Cancer Institute (NCI)
- Study on Adding Whole Brain Radiotherapy with Memory Protection to Targeted Brain Radiation for Cancer Spread to the Brain — NRG Oncology
- Testing Targeted Treatment (AMG 510) for Advanced Lung Cancer with KRAS G12C Mutation — SWOG Cancer Research Network
About this hub
Expanded access programs (sometimes called compassionate use, named-patient programs, or pre-approval access) allow patients with serious or life-threatening conditions such as Stage IV Lung Cancer AJCC v8 to receive an investigational therapy outside of a controlled clinical trial when no comparable approved option is available. Eligibility, location, and the application process differ for each program — review the individual program pages below for sponsor contact information, inclusion criteria, and the request workflow. Right2Hope is a 501(c)(3) nonprofit and provides this directory free of charge for patients, caregivers, and treating physicians.
Looking for a different condition? Browse the full Cancer Type hub directory or search the full expanded access program catalog.